Vyome Holdings (HIND) Long-Term Investments (2024 - 2026)

Vyome Holdings (HIND) posted quarterly Long-Term Investments of $2609.0 for Q1 2026, down 20.02% quarter-over-quarter from $3262.0 in Q4 2025.

Vyome Holdings (HIND) Long-Term Investments (2024 - 2026) Analysis & Trends

Vyome Holdings' Long-Term Investments history runs 3 years deep, the most recent figure standing at $2609.0 for Q1 2026.

In Q1 2026, Long-Term Investments changed N/A year-over-year to $2609.0; the TTM figure through Mar 2026 stood at $2609.0 (changed N/A YoY), while the FY2025 annual figure was $3262.0, down 73.12% from the prior year.
Long-Term Investments for Q1 2026 stood at $2609.0, down from $3262.0 in the prior quarter.
The five-year high for Long-Term Investments was $12134.0 in Q4 2024, with the low at $2609.0 in Q1 2026.
The 3-year median for Long-Term Investments is $5159.5 (2025), against an average of $6265.5.
Peak annual rise in Long-Term Investments reached 73.12% in 2025, while the deepest fall reached 73.12% in 2025.
Vyome Holdings' Long-Term Investments stood at $12134.0 in 2024, then sank by 73.12% to $3262.0 in 2025, then decreased by 20.02% to $2609.0 in 2026.
Business Quant data shows HIND's Long-Term Investments at $2609.0 in Q1 2026, $3262.0 in Q4 2025, and $7057.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	Vyome Holdings	16.07 Mn	8.18 Mn	11,658.00	5,336.00

Download Data